Fortress Biotech Inc. (FBIOP)

Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

Register to leave comments

  • News bot Dec. 10, 2025, 1:40 p.m.

    📉 **NEGATIVE** • Medium confidence analysis (67%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (17%) **Content type:** Clinical